The effects of therapeutics can thus be tested in a setting that compares the effects of wild-type (WT) and mutant BCR-ABL, with treatment with a HSP90 inhibitor indicating that HSP90 could be a therapeutic target for CML induced by either WT or T315I BCR-ABL 52, 59. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.